AbbVie, Obesity and Licensing Deal

AbbVie Joins Obesity Treatment Market With Up to $2.2B Licensing Deal
Key Takeaways AbbVie agreed to license a weight-loss drug in development from Danish biotech firm Gubra.AbbVie said it will pay up to about $2.2 billion for the drug GUBamy, which is currently in a Phase 1 clinical trial.
AbbVie gets into obesity with $350M deal for once-weekly shot
A licensing deal with Denmark’s Gubra gives the immunology giant control of an experimental therapy that could compete with drugs from Novo Nordisk, Eli Lilly and Zealand.
AbbVie, Gubra in Obesity-Drug License Pact Potentially Worth More Than $2 Billion
AbbVie is jumping into the burgeoning obesity field, striking a license agreement with Gubra that is potentially worth more than $2 billion to the Danish drug-discovery and contract-research-services company.
AbbVie enters obesity drug market with Danish drugmaker
AbbVie has signed a licensing deal with Gubra A/S to develop an obesity drug, marking the North Chicago company's first foray into the obesity market.
AbbVie and Gubra Announce License Agreement to Develop an Amylin Analog for the Treatment of Obesity
AbbVie (NYSE: ABBV) and Gubra A/S (CPSE:GUBRA), a company specializing in preclinical contract research services and peptide-based drug discovery within metabolic and fibrotic diseases, today announced a license agreement to develop GUB014295,
AbbVie Enters Obesity Market Through Licensing Deal With Denmark's Gubra
AbbVie (ABBV) on Monday said it struck a licensing deal with Danish biotechnology company Gubra to develop a potential candidate for obesity treatment. AbbVie will be responsible for the global development and commercialization activities of GUB014295,
Healthy Returns: AbbVie is the newest potential weight loss drug market player
AbbVie will pay up to $2.2 billion to develop Danish drugmaker Gubra’s obesity drug. AI takes center stage at HIMSS ...
Investor's Business Daily on MSN1d
AbbVie Enters The Obesity Arena. Why It's Paying Up To $2.23 Billion.
AbbVie inked a licensing deal Monday worth up to $2.23 billion for an amylin-targeting obesity treatment from Denmark-based ...
AbbVie Steps Into The Ring In The Obesity Drug Wars
AbbVie's strategic move into the obesity market through a partnership with Gubra A/S shows potential but won't impact revenue ...
STAT1d
AbbVie steps into the obesity drug race, licensing medicine from Danish firm
The obesity medicine field has gained a new entrant, with AbbVie licensing an experimental drug from a Danish company.
FierceBiotech1d
AbbVie pays Gubra $350M to make late play for obesity space
AbbVie is paying $350 million to join the obesity race. The outlay, plus up to $1.875 billion in milestones, has landed the ...
AbbVie price target raised to $223 from $200 at BofA
BofA raised the firm’s price target on AbbVie (ABBV) to $223 from $200 and keeps a Neutral rating on the shares after the company and Gubra ...
AbbVie, Reddit, Allegro MicroSystems: Market Minute
Yahoo Finance host Josh Lipton tracks the day's biggest stocks in this Market Minute. AbbVie (ABBV) announced a licensing ...